Research programme: cancer therapeutics - Myrexis

Drug Profile

Research programme: cancer therapeutics - Myrexis

Alternative Names: MPC-0767; MPI-0479605; MPI-479605; MPI-487109; MPI-487901; MPYS 197; MPYS 413

Latest Information Update: 27 Feb 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Feb 2014 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPC 0767 is available for out-licensing; Myrexis does not intend to further develop the compound itself (\www.myrexis.com\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top